ATE372112T1 - Enantiomere amphetamine enthaltende zusammensetzungen zur behandlung von aufmerksamkeitsdefizit-/hyperaktivitätsstörung (adhd) - Google Patents
Enantiomere amphetamine enthaltende zusammensetzungen zur behandlung von aufmerksamkeitsdefizit-/hyperaktivitätsstörung (adhd)Info
- Publication number
- ATE372112T1 ATE372112T1 AT04709870T AT04709870T ATE372112T1 AT E372112 T1 ATE372112 T1 AT E372112T1 AT 04709870 T AT04709870 T AT 04709870T AT 04709870 T AT04709870 T AT 04709870T AT E372112 T1 ATE372112 T1 AT E372112T1
- Authority
- AT
- Austria
- Prior art keywords
- amphetamines
- adhd
- treatment
- compositions containing
- attention deficit
- Prior art date
Links
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 title 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 title 2
- 239000000203 mixture Substances 0.000 title 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 abstract 2
- KWTSXDURSIMDCE-MRVPVSSYSA-N (R)-amphetamine Chemical compound C[C@@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-MRVPVSSYSA-N 0.000 abstract 1
- 229940025084 amphetamine Drugs 0.000 abstract 1
- 229960000632 dexamfetamine Drugs 0.000 abstract 1
- 229950005223 levamfetamine Drugs 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44579303P | 2003-02-10 | 2003-02-10 | |
| US47392503P | 2003-05-29 | 2003-05-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE372112T1 true ATE372112T1 (de) | 2007-09-15 |
Family
ID=32871959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04709870T ATE372112T1 (de) | 2003-02-10 | 2004-02-10 | Enantiomere amphetamine enthaltende zusammensetzungen zur behandlung von aufmerksamkeitsdefizit-/hyperaktivitätsstörung (adhd) |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20040220277A1 (de) |
| EP (1) | EP1626709B1 (de) |
| JP (1) | JP2006517232A (de) |
| KR (1) | KR20050119106A (de) |
| AT (1) | ATE372112T1 (de) |
| AU (1) | AU2004210671A1 (de) |
| CA (1) | CA2515394A1 (de) |
| DE (1) | DE602004008771T2 (de) |
| ES (1) | ES2293223T3 (de) |
| WO (1) | WO2004071501A1 (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6913768B2 (en) * | 2002-09-24 | 2005-07-05 | Shire Laboratories, Inc. | Sustained release delivery of amphetamine salts |
| US9713592B2 (en) | 2005-04-06 | 2017-07-25 | Mallinckrodt Llc | Matrix-based pulse release pharmaceutical formulation |
| WO2007041571A1 (en) * | 2005-10-03 | 2007-04-12 | Cambrex Charles City, Inc. | Improved method of making amphetamine free base |
| CA2645855C (en) | 2006-03-16 | 2015-02-03 | Tris Pharma, Inc. | Modified release formulations containing drug-ion exchange resin complexes |
| GB201002612D0 (en) * | 2010-02-16 | 2010-03-31 | Jagotec Ag | Improvements in or relating to organic compounds |
| ES2689520T3 (es) | 2010-04-23 | 2018-11-14 | Kempharm, Inc. | Formulación terapéutica para reducir los efectos secundarios de fármacos |
| US8287903B2 (en) | 2011-02-15 | 2012-10-16 | Tris Pharma Inc | Orally effective methylphenidate extended release powder and aqueous suspension product |
| US9603809B2 (en) | 2011-03-23 | 2017-03-28 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
| US10292937B2 (en) | 2011-03-23 | 2019-05-21 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
| US10905652B2 (en) | 2011-03-23 | 2021-02-02 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US9498447B2 (en) | 2011-03-23 | 2016-11-22 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US9283214B2 (en) | 2011-03-23 | 2016-03-15 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US11241391B2 (en) | 2011-03-23 | 2022-02-08 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US9119809B2 (en) | 2011-03-23 | 2015-09-01 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| WO2013059676A1 (en) | 2011-10-21 | 2013-04-25 | Subhash Desai | Compositions for reduction of side effects |
| US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
| CA3015500A1 (en) * | 2016-02-24 | 2017-08-31 | Chemapotheca, Llc | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms |
| US12458592B1 (en) | 2017-09-24 | 2025-11-04 | Tris Pharma, Inc. | Extended release amphetamine tablets |
| US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
| AU2022283967A1 (en) | 2021-06-03 | 2024-01-18 | Arcadia Medicine, Inc. | Enantiomeric entactogen compositions and methods of their use |
| CA3239514A1 (en) * | 2021-12-09 | 2023-06-15 | Matthew J. Baggott | Specialized combinations for mental disorders or mental enhancement |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL131713A (en) * | 1997-03-11 | 2004-08-31 | Arakis Ltd | Dosage forms comprising separate portions of r- and s-enantiomers |
| US20010055613A1 (en) * | 1998-10-21 | 2001-12-27 | Beth A. Burnside | Oral pulsed dose drug delivery system |
| WO2000059479A1 (en) * | 1999-04-06 | 2000-10-12 | Pharmaquest Ltd. | Pharmaceutical dosage form for pulsatile delivery of methylphenidate |
| WO2002039998A2 (en) * | 2000-11-01 | 2002-05-23 | Sention, Inc. | Methods and compositions for regulating memory consolidation |
| EP1487448A4 (de) * | 2002-02-28 | 2007-04-25 | Sempach Pty Ltd | Behandlung der auswirkung von chemikalien mit ihren ultraverdünnten stereoisomeren |
| AU2003231156A1 (en) * | 2002-04-30 | 2003-11-17 | Npd Llc | Multi-phasic delivery via transmucosal absorption of appetite suppressants and craving reduction medicaments |
| US6913768B2 (en) * | 2002-09-24 | 2005-07-05 | Shire Laboratories, Inc. | Sustained release delivery of amphetamine salts |
-
2004
- 2004-02-10 WO PCT/US2004/003821 patent/WO2004071501A1/en not_active Ceased
- 2004-02-10 AT AT04709870T patent/ATE372112T1/de not_active IP Right Cessation
- 2004-02-10 AU AU2004210671A patent/AU2004210671A1/en not_active Abandoned
- 2004-02-10 JP JP2006503445A patent/JP2006517232A/ja active Pending
- 2004-02-10 CA CA002515394A patent/CA2515394A1/en not_active Abandoned
- 2004-02-10 ES ES04709870T patent/ES2293223T3/es not_active Expired - Lifetime
- 2004-02-10 KR KR1020057014628A patent/KR20050119106A/ko not_active Withdrawn
- 2004-02-10 DE DE602004008771T patent/DE602004008771T2/de not_active Expired - Fee Related
- 2004-02-10 EP EP04709870A patent/EP1626709B1/de not_active Expired - Lifetime
- 2004-02-10 US US10/774,697 patent/US20040220277A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004210671A1 (en) | 2004-08-26 |
| KR20050119106A (ko) | 2005-12-20 |
| EP1626709A1 (de) | 2006-02-22 |
| ES2293223T3 (es) | 2008-03-16 |
| EP1626709B1 (de) | 2007-09-05 |
| DE602004008771T2 (de) | 2008-06-12 |
| US20040220277A1 (en) | 2004-11-04 |
| CA2515394A1 (en) | 2004-08-26 |
| WO2004071501A1 (en) | 2004-08-26 |
| HK1091117A1 (en) | 2007-01-12 |
| JP2006517232A (ja) | 2006-07-20 |
| DE602004008771D1 (de) | 2007-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE372112T1 (de) | Enantiomere amphetamine enthaltende zusammensetzungen zur behandlung von aufmerksamkeitsdefizit-/hyperaktivitätsstörung (adhd) | |
| DE122005000011I1 (de) | Verwendung von Tomoxet in zur Behandlung von Hyperaktivit{t mit Aufmerksamkeitsstörungen. | |
| DE602004030239D1 (de) | Verfahren und zwischenprodukte zur herstellung von (1r,2s,5s)-6,6-dimethyl-3-azabicycloä3,1,0 ühexan-2-carboxylaten oder salzen davon | |
| EA200801243A1 (ru) | Фармацевтическое применение замещенных амидов | |
| ATE361084T1 (de) | Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis | |
| DE602004031134D1 (de) | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa | |
| ATE529125T1 (de) | Pharmazeutische zusammensetzungen und verfahren zur beschleunigung der wundheilung | |
| ATE346614T1 (de) | Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung | |
| DE502005008058D1 (de) | Gesättigte und ungesättigte 3-pyridyl-benzocycloalkylmethyl-amine zur behandlung von schmerzen, depressionen und angstzuständen | |
| FR2873379B1 (fr) | Procede de preparation d'acide hyaluronique reticule, acide hyaluronique reticule susceptible d'etre obtenu par ledit procede, implant contenant ledit acide hyaluronique reticule, et son utilisation | |
| DE60118956D1 (de) | Calciumkanalantagonisten vom n-typ zur behandlung von schmerzen | |
| NO20064373L (no) | 5-aminolevulinsyresalt, fremgangsmate for dets fremstilling og anvendelse derav | |
| ATE543491T1 (de) | Kombinationspräparat enthaltend ibuprofen und paracetamol | |
| BR0309728A (pt) | Composição implantável, e, métodos para produzir a mesma, e para o tratamento eficaz de cartilagem de superfìcie de junta articulante | |
| ATE502631T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
| ATE306915T1 (de) | Verwendung eines kombinationspräparates aus vitamin-d-metaboliten oder vitamin-d-analoga und eines östrogenpartialagonisten zur behandlung von osteoporose | |
| DE60238765D1 (de) | Carbamatverbindungen zur behandlung von schmerz | |
| EA200700637A1 (ru) | Соли донепезила, подходящие для получения фармацевтических композиций | |
| BRPI0408680A (pt) | processo para produzir álcoois e aminas enantiomericamente enriquecidos | |
| SE0402507D0 (sv) | Medicinsk lösning, förfarande för framställning och användning därav | |
| CY1110156T1 (el) | Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης | |
| SE0101256D0 (sv) | Treatment of low back pain | |
| ATE283020T1 (de) | Biomaterial zur behandlung von zahnfäule | |
| DE60022033D1 (de) | Therapeutische verwendung von d-threo-methylphenidate zur behandlung von aufmerksamkeitsmangel-hyperaktivitätsstörungen | |
| ATE442122T1 (de) | Dentalmaterial mit bakteriostatischen und/oder bakteriziden substanzen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |